Atorvastatin prevents hearing impairment in the presence of hyperlipidemia

Biochim Biophys Acta Mol Cell Res. 2020 Dec;1867(12):118850. doi: 10.1016/j.bbamcr.2020.118850. Epub 2020 Sep 9.

Abstract

It is known that hyperlipidemia is a risk factor for sensorineural hearing loss. However, the biological mechanisms underlying hyperlipidemia and hearing impairment have not been completely elucidated in the cochlea. Based on our previous study of human subjects, elderly people taking drugs for hyperlipidemia showed better hearing than those not taking any medications. We hypothesized that drugs for hyperlipidemia, such as statins, may have the potential to prevent hearing impairment. The aim of this study was to investigate the correlation between hyperlipidemia and hearing impairment and the hearing preservation effect of atorvastatin using a hyperlipidemic mouse model with diet-induced obesity (DIO). Here, we demonstrate that DIO mice had a significant hearing impairment as well as increased levels of reactive oxygen species (ROS) and hair cell death due to reduced levels of pAKT and superoxide dismutase 2 (SOD2). However, these changes were significantly prevented by atorvastatin. Oxidative stress-induced intrinsic apoptosis was decreased by the high expression of Nrf2 and antioxidant genes, which improved mitochondrial function and ROS via activation of the PI3K-pAKT pathway by atorvastatin. Therefore, atorvastatin has the potential to prevent hearing impairment via redox balance in the presence of hyperlipidemia.

Keywords: Apoptosis; Atorvastatin; Hearing impairment; Hyperlipidemia; ROS; pAKT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Animals
  • Antioxidants / pharmacology
  • Apoptosis / drug effects
  • Atorvastatin / pharmacology*
  • Cochlea / drug effects
  • Cochlea / metabolism
  • Cochlea / pathology
  • Diet, High-Fat / adverse effects
  • Disease Models, Animal
  • Hearing Loss / drug therapy*
  • Hearing Loss / etiology
  • Hearing Loss / genetics
  • Hearing Loss / pathology
  • Humans
  • Hyperlipidemias / complications
  • Hyperlipidemias / drug therapy*
  • Hyperlipidemias / genetics
  • Hyperlipidemias / pathology
  • Male
  • Mice
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Oxidation-Reduction
  • Oxidative Stress / drug effects*
  • Reactive Oxygen Species / metabolism
  • Signal Transduction / drug effects

Substances

  • Antioxidants
  • Reactive Oxygen Species
  • Atorvastatin